Purpose Clinical PET/MR acquisition protocols entail the use of MR contrast agents (MRCA) that could potentially affect PET quantification following MR-based attenuation correction (AC). We assessed the effect of oral and intravenous (IV) MRCA on PET quantification in PET/MR imaging. Methods We employed two MRCA: Lumirem® (oral) and Gadovist® (IV). First, we determined their reference PET attenuation values using a PET transmission scan (ECAT-EXACT HR+, Siemens) and a CT scan (PET/CT Biograph 16 HI-REZ, Siemens). Second, we evaluated the attenuation of PET signals in the presence of MRCA. Phantoms were filled with clinically relevant concentrations of MRCA in a background of water and 18 F-fluoride, and imaged using a PET/CT scanner (Biograph 16 HI-REZ, Siemens) and a PET/ MR scanner (Biograph mMR, Siemens). Third, we investigated the effect of clinically relevant volumes of MRCA on MR-based AC using human pilot data: a patient study employing Gadovist® (IV) and a volunteer study employing two different oral MRCA (Lumirem® and pineapple juice). MR-based attenuation maps were calculated following Dixonbased fat-water segmentation and an external atlas-based and pattern recognition (AT&PR) algorithm. Results IV and oral MRCA in clinically relevant concentrations were found to have PET attenuation values similar to those of water. The phantom experiments showed that under clinical conditions IV and oral MRCA did not yield additional attenuation of PET emission signals. Patient scans showed that PET attenuation maps are not biased after the administration of IV MRCA but may be biased, however, after ingestion of iron oxide-based oral MRCA when segmentation-based AC algorithms are used. Alternative AC algorithms, such as AT&PR, or alternative oral contrast agents, such as pineapple juice, can yield unbiased attenuation maps. Nucl Med Mol Imaging (2012) 39:1756-1766 DOI 10.1007/s00259-012-2190 PET emission signals. MR-based attenuation maps may be biased by oral iron oxide-based MRCA unless advanced AC algorithms are used.
employing Gadovist® (IV) and a volunteer study employing two different oral MRCA (Lumirem® and pineapple juice). MR-based attenuation maps were calculated following Dixonbased fat-water segmentation and an external atlas-based and pattern recognition (AT&PR) algorithm. Results IV and oral MRCA in clinically relevant concentrations were found to have PET attenuation values similar to those of water. The phantom experiments showed that under clinical conditions IV and oral MRCA did not yield additional attenuation of PET emission signals. Patient scans showed that PET attenuation maps are not biased after the administration of IV MRCA but may be biased, however, after ingestion of iron oxide-based oral MRCA when segmentation-based AC algorithms are used. Alternative AC algorithms, such as AT&PR, or alternative oral contrast agents, such as pineapple juice, can yield unbiased attenuation maps. Conclusion In clinical PET/MR scenarios MRCA are not expected to lead to markedly increased attenuation of the
Introduction
Combined whole-body PET/MR systems for clinical research and applications were first introduced in 2010 [1] . By 2012, about 30 systems are expected to be operational worldwide. All commercially available PET/MR systems for use in humans integrate a 3-T MR scanner and a fullring, whole-body PET or PET/CT system [2, 3] . The first design concept proposed combines a 3-T MR scanner and a time-of-flight PET scanner [4] with a joint table platform in between [5, 6] , referred to as a "coplanar PET/MR" system. The second design concept consists of a 3-T MR scanner equipped with an integrated APD-based, full-ring PET detector system mounted inside the gradient coil of the MR scanner and covering an axial field-of-view of 26 cm [7] . This design is referred to as a "fully integrated PET/MR" system, the only system that offers the capability of simultaneous PET and MR imaging. A third design was proposed in late 2010 and combines a whole-body PET/CT system with a 3-T MR scanner arranged in two adjacent rooms with patients being moved between the two systems on a shuttle bed [8] . This system is referred to as a "side-by-side PET/ MR" system. Both the integrated and the coplanar PET/MR systems require MR images for attenuation correction (AC) [9] [10] [11] [12] , while the side-by-side PET/MR system utilizes standard CT-based AC [13] . All systems are currently in clinical testing.
Much like PET/CT applications, the clinical adoption of PET/MR entails the use of contrast agents as part of integrated imaging protocols. MR contrast agents (MRCA) are typically made up of iron oxide and Gd-chelates for oral and intravenous (IV) administration, respectively [14] . It is known from the development of CT-based AC that the presence of contrast materials with effective atomic numbers higher than that of water may lead to biased attenuation maps for PET emission data [15] [16] [17] . The same effects may occur with MRCA that are administered during PET/ MR imaging. In PET/MR the attenuation map can be calculated from the MR images through different approaches such as intensity-based tissue segmentation or atlas registration and pattern recognition (AT&PR) [9] . Segmentation algorithms classify the MR data into different tissue types and assign predefined attenuation coefficients to the voxels of each class [10, 11] . The AT&PR method utilizes a database of prealigned MR/CT image volumes. For each patient, these pairs are registered to the MR volume from actual study, and a pattern recognition approach is used to predict the attenuation values on a continuous scale [12] . Both approaches may be affected by the presence of MRCA since these produce changes in the MR signal intensity or because they attenuate the PET emission signal without being recognized as an attenuator stronger than water (i.e. soft tissue).
In the study reported here, we assessed the effect of MRCA on PET quantification in integrated PET/MR imaging using either coplanar or integrated PET/MR systems. First, we determined reference attenuation values of commonly used IV and oral MRCA at various concentrations. Second, we evaluated the attenuation of the PET emission signal in the presence of clinically relevant concentrations of IV and oral MRCA. Third, we evaluated the effect of a biased attenuation map on the accuracy of PET quantification. Finally, we investigated how the presence of clinically relevant volumes of IV and oral MRCA affect the MR-based attenuation maps in patient studies.
Materials and methods

MR contrast agents
Two commonly available MRCA were evaluated: ferumoxil (Lumirem®; Guerbet, Germany) and gadobutrol (Gadovist®; Bayer Vital, Germany). Ferumoxil is a negative oral contrast agent used to distinguish the loops of the bowel from other abdominal structures. It contains a colloid suspension of iron oxide particles, and has superparamagnetic properties [18] [19] [20] . Gadobutrol is an IV contrast agent that consists of a neutral macrocyclic gadolinium complex that has paramagnetic properties [21] [22] [23] . For comparison, the iodine-based CT IV contrast agent iomeprol [24] (Imeron® 400 MCT; Bracco Imaging, Germany) was also used.
Reference PET attenuation values of the contrast agents were determined with a transmission scan using a 68 Ge line source in a PET tomograph (ECAT EXACT HR+; Siemens [25] ). Six syringes of 5 ml each (12 mm in diameter and 65 mm in height) were filled with (1) water, (2) Lumirem® (100 % concentration), (3) Gadovist® (100 %), (4) Imeron® 400 MCT (100 %), (5) Gadovist® (0.2 %), and (6) Imeron® 400 MCT (2.4 %). The employed concentrations correspond to undiluted and clinically relevant concentrations of MR and CT contrast agents, respectively. Clinically relevant concentrations of IV MRCA in organs and vessels are very low, with 5-7 ml of a 1 mmol/ml MRCA solution injected into adult patients (assuming a 5-7 l blood volume). To account for increased amounts of injected MRCA, we elected to double this concentration to about 0.2 % for our phantom experiments, in order to obtain a clinically relevant steady-state concentration. The concentrations of IV CT contrast agents were higher due to the larger administered volumes and more restricted distribution volumes (typically 120-130 ml of a 400 mg/ml iodine solution injected into adults with a blood volume of 5-7 l).
The syringes were centred in the field-of-view and scanned for 12 h in 2-D transmission mode with extended septa. Transmission data were FORE-rebinned and reconstructed by filtered back-projection using direct Fourier reconstruction [26] (128×128 image matrix, with 2 mm in-plane pixel size and 2.4 mm slice thickness; 6 mm gaussian filter).
The same set of syringes was imaged on a multislice CT scanner (PET/CT Biograph 16 HI-REZ; Siemens [27] ) at 120 kVp, 160 mAs. CT images were reconstructed using filtered back-projection (512×512 image matrix, with 1 mm in-plane pixel size and 1 mm slice thickness; B31f filter).
The resulting 511 keV attenuation values (cm −1 ) were calculated from the transmission images by drawing cylindrical volumes-of-interest (VOI) of diameter 7 mm and height 25 mm centred in each syringe. The corresponding CT mean attenuation values (Hounsfield units; HU) used for the computation of the AC coefficients in PET/CT imaging were obtained using the same VOI analysis as above.
Phantom studies
Three phantom experiments were performed on a clinical PET/CT scanner (Biograph 16 HI-REZ; Siemens [27] ) and an integrated whole-body PET/MR scanner (Biograph mMR; Siemens [7] ). The first phantom experiment (phantom A) was performed to assess the effect of clinically relevant concentrations of IV and oral MRCA on PET quantification in PET/ MR. A cylinder of diameter 20 cm and length 20 cm [28] was filled uniformly with a solution of 18 F and water (Fig. 1a) . Three cylinders of diameter 4.5 cm and height 18.3 cm were inserted into the phantom: Teflon (C1), Lumirem® + 18 F (C2), and water + 18 F (C3). The cylinders were filled with an activity concentration twice that of the background. Two 50-ml syringes of diameter 2.6 cm and height 11.4 cm were attached to the sides of C1 to mimic the effects of IV contrast in vessels near bone: Gadovist® (0.2 %) + 18 F (Sy1), and water + 18 F (Sy2). The syringes were filled with an activity concentration four times that of the background. The total activity in the phantom was 40 MBq at the start of the measurement.
PET/CT and PET/MR data were acquired with the phantom (Fig. 1a) centred in each field-of-view. The PET/CT acquisition included a topogram followed by a CT scan (120 kVp, 180 mAs) and a 3-D PET emission scan of 10 min. Three-dimensional PET images were reconstructed with OSEM-2D (4 iterations, 8 subsets; 256×256 image matrix, with 2.7 mm in-plane pixel size and 2 mm slice thickness; 5 mm gaussian filter) using conventional CT-based AC [13] . The PET/MR acquisition included a localizer followed by simultaneous 3-D PET and MR acquisitions with the PET data acquired for 10 min. Several MR sequences were acquired, including two that could be used for AC: T1-weighted FLASH with Dixon-based fat-water segmentation, designed specifically for patients (TR 3.6 ms, echo time TE 1 subsets; 256×256 image matrix, with 2.8 mm in-plane pixel size and 2 mm slice thickness; 5 mm gaussian filter) using the UTE sequence for MR-based AC. Since the appearance of Teflon and that of air on MR images are similar, MRbased AC assigned incorrect (air) attenuation coefficients to the Teflon insert (C1). In addition, the phantom acrylic glass encasing is not visible on MR images, and therefore in MRbased AC the corresponding attenuation of the annihilation photons is not accounted for. In order to take this bias into account, the CT-based attenuation map from the PET/CT acquisition was aligned manually with the uncorrected emission data from the PET/MR acquisition and used for the reconstruction of AC PET images. The assigned PET attenuation values were 0.096 cm −1 (water), 0.190 cm −1 (Teflon), 0.097 cm −1 (Lumirem®), and 0.0962 cm
Lesion-to-background ratios (LBR) were measured in the different cylinder and syringe phantom inserts. LBR are defined as the mean activity value in a VOI divided by the mean activity value in the background. Cylindrical VOIs were centred on each insert cylinder (of diameter 30 mm and height 80 mm), and on each syringe (of diameter 15 mm and height 80 mm). The background activity was calculated as the mean value of three cylindrical VOIs of diameter 30 mm and height 80 mm placed in the uniform body phantom. To determine whether the presence of MRCA led to an increase in attenuation of PET signals in relation to water, LBR were compared between the cylinders C2 and C3, and between the syringes Sy1 and Sy2.
The second phantom experiment (phantom B) was performed to further assess the effect of oral MRCA, and was designed to simulate bile duct lesions with more realistic distributions of oral MRCA and activity inside the body. A NEMA image quality phantom [29] (Fig. 1b) was filled with a solution of 18 F and water. The spheres were used to simulate lesions of different sizes (of diameter 10, 13, 17, 22, 28 and 37 mm), and were filled with an activity concentration of four times that of the background. The central lung insert was used to simulate the stomach where the oral contrast agent remains during examination. In a first set-up (L1) the insert was filled with water + 18 F, and in a repeat set-up (L2) the insert was filled with Lumirem® + 18 F; in both experiments, the activity concentration of the insert and the background were the same. Phantom B data were acquired on the PET/CT and PET/MR scanners on two different days. During the PET/CT acquisition, the total activity in the field-of-view was 90 MBq. The acquisition protocol was a topogram followed by a CT scan (120 kVp, 180 mAs), and 3-D PET emission data were then acquired for 5 min. Threedimensional PET images were reconstructed with OSEM-2D (4 iterations, 8 subsets; 256×256 image matrix, with 2.7 mm in-plane pixel size and 2 mm slice thickness; 5 mm gaussian filter) using conventional CTbased AC [13] .
During the PET/MR acquisition, the total activity in the field-of-view was 20 MBq. The acquisition protocol included a localizer followed by simultaneous PET and MR acquisitions. Three-dimensional PET emission data were acquired for 15 min. Several MR sequences were applied, including two standard sequences that can be used for AC (T1-weighted FLASH with Dixon-based fat-water segmentation, and UTE). PET emission data of the NEMA quality phantom were corrected for attenuation and scatter using CT-based AC [7] , since the MR-based attenuation maps showed severe image distortions, including brightening and darkening, due to resonance artefacts arising from the large phantom size in combination with the phantom filling providing a high dielectric constant [30] . As with the first phantom experiment, CT-based attenuation maps were calculated from the CT data acquired in the PET/CT scan by piece-wise linear scaling [31] , and manually aligned with the uncorrected PET emission data. Attenuation-corrected emission images were reconstructed with OSEM-3D (3 iterations, 21 subsets, 256 × 256 image matrix, with 2.8 mm in-plane pixel size and 2 mm slice thickness; 5 mm gaussian filter). To determine whether the presence of oral MRCA produces an increased attenuation of PET signals in relation to water, the LBR measured at the spheres were compared between experiments L1 and L2. Spherical VOIs with dimensions of 70 % of their physical size were centred on each of the spheres and the mean values and standard deviations were computed. The background was measured as the mean value of seven cylindrical VOIs of diameter 30 mm and height 30 mm placed in the uniform body phantom.
The third phantom experiment (phantom C) was performed to determine the influence of a biased attenuation map on PET quantification. Data from the PET/(MR) scan of phantom B (experiment L2 described above) were reconstructed using three different attenuation maps. Volunteer and patient studies A pilot study including one patient and one volunteer was performed on a clinical whole-body PET/MR scanner (Biograph mMR, Siemens) to investigate the effect of IV and oral MRCA on MR-based AC of PET data. This pilot study was approved by the local ethics committee.
IV contrast agent
To investigate the effect of IV MRCA on the attenuation maps, a patient with bronchial carcinoma underwent a PET/ MR scan before and after the administration of 6 ml of Gadovist® (1 mmol/ml). The study was acquired 122 min after IV injection of 381 MBq of 18 F-FDG. During the 6 min per bed PET acquisition, the MR sequence routinely used for AC was applied (T1-weighted FLASH sequence with Dixon-based fat-water segmentation). Attenuation maps were calculated using two methods. First, we used an intensity-based segmentation algorithm that is the standard method provided with the PET/MR system. The in-phase, opposed phase and Dixon fat and water images are used to segment the tissue into four classes (air, lung, fat and waterbased tissue) and predefined attenuation coefficients are assigned to the voxels of each class. Second, we used an AT&PR algorithm that utilizes a database of aligned MR/CT image volumes to obtain the attenuation values [9, 12] . Each MR image from the MR/CT pairs is coregistered to the MR image from the PET/MR study, and the coregistration vectors are then applied to the corresponding CT image volumes. Subsequently, gaussian process regression is used to predict (pseudo-)CT values on a continuous scale, and these values are then converted to attenuation coefficients via piece-wise linear scaling. The prediction weights the CT values from the atlas database based on the similarity between the local neighbourhood of each voxel from the patient image and the neighbourhoods of the voxels in the MR image atlas [12] .
PET data were reconstructed with OSEM-3D (3 iterations, 21 subsets; 172×172 image matrix, with 4.2 mm inplane pixel size and 2 mm slice thickness; 3 mm gaussian filter) using both the segmentation-based and AT&PR algorithms for AC.
The data from the patient study were analysed using manually defined VOIs placed on different reference tissues (liver, fat, lung, muscle, aorta, bone) of the MR images, attenuation maps, and AC PET images. Figure 2 shows some examples of the defined VOIs. Mean values obtained in the studies acquired with and without IV contrast agent were compared.
Oral contrast agent
To investigate the effect of oral MRCA on the attenuation maps, a volunteer underwent three MR scans on the PET/ MR system. The first scan was a non-enhanced MR scan performed after the volunteer had fasted for 8 h, the second scan 15 min after the volunteer had ingested 300 ml of Lumirem®, the standard oral MRCA used at our hospital, and the third scan on a different day after the volunteer had fasted for 8 h and 15 min after ingestion of 400 ml of manganese-containing pineapple juice as an alternative oral a b c MRCA [32, 33] . For each scan, the MR sequences routinely used for AC (T1-weighted FLASH sequence with Dixon-based fat-water segmentation) were applied. Attenuation maps were calculated using both the intrinsic segmentation-based and the AT&PR algorithms described above. VOI analysis was performed by a senior radiologist (N.S. with 8 years experience). A manually defined VOI inside the stomach was drawn on the MR images and copied to the attenuation maps. The mean attenuation values obtained with and without MRCA were compared. Table 1 lists mean linear PET attenuation on the transmission images and the corresponding CT values used for the computation of CT-based AC coefficients. Undiluted IV MRCA have attenuation values similar to those of IV CT contrast agents. IV and oral MRCA in clinically relevant concentrations have attenuation values similar to that of water. The values obtained from the transmission scans were lower than expected due to the small volume of the syringes and partial volume effects, which are the same for all 5-ml syringes.
Results
MR contrast agents
Phantom studies
Phantom A Phantom A is illustrated in (Fig. 1a) , and VOIbased LBRs are given in Table 2 for the different phantom inserts. Oral MRCA (Lumirem®) had little clinically relevant effect on PET attenuation. After normalization of the LBR measured on C2 and C3 to the injected activity in each case measured with the well counter ("true LBR"), C3 was found to be 13 %, 10 %, and 12 % higher than C2 on PET/ CT, PET/MR with MR-based AC, and PET/MR with CTbased AC, respectively. The IV MRCA (Gadovist® 0.2 %) had smaller effects with Sy1 being −2.5 %, +1.2 %, and −3.9 % with respect to Sy2 on PET/CT, PET/MR with MRbased AC, and PET/MR with CT-based AC, respectively.
Phantom B Phantom B is illustrated in (Fig. 1b) , and Table 3 shows mean LBRs measured in the spheres of different sizes for the experiments performed on the PET/ CT and PET/MR with water (L1) or oral MRCA (L2) in the inner cylinder. No substantial differences between L1 and L2 were found, neither for the PET/CT nor for the PET/MR data. This indicates that oral MRCA produced no additional attenuation of the PET signals compared to water. This result was independent of the lesion size, despite LBR variations with sphere size due to partial volume effects.
Phantom C Table 4 shows mean LBRs measured in the spheres of different sizes for the PET/(MR) images reconstructed using the original CT-based AC (M1) and the modified attenuation maps with attenuation values in the central cylinder of water (M2) and air (M3). No differences were found between M1 and M2, which indicates that the accuracy of PET quantification is not affected when oral MRCA is considered as water for AC purposes. Small differences of up to 3.5 % (within the error margins, but consistent for all lesion sizes) were found between M3 and M1, which indicates that a small bias is introduced when oral contrast is considered as air for AC purposes. The effect was, however, greatly increased for the central cylinder, i.e. the volume assigned with the incorrect attenuation values. Quantification in this volume could be severely biased, with LBR differences of about 90 %.
Volunteer and patient studies IV MRCA Figure 2 shows coronal MR images and the attenuation maps calculated both with the standard segmentation-based and the AT&PR algorithms for the patient studies performed before and after IV administration of MRCA. Table 5 shows the mean attenuation values of various tissue types. Differences between the attenuation values obtained with and without IV MRCA were found to be below 0.5 % and 3 % with the segmentation and AT&PR algorithms, respectively. AC PET values obtained with and without IV MRCA could not be directly compared due to the different study conditions.
Oral MRCA Figure 3 shows coronal views of the three MR scans performed in the volunteer: non-enhanced, after ingestion of Lumirem®, and after ingestion of pineapple juice. For each study, the MR image and the attenuation maps obtained with the standard segmentation-based and the AT&PR algorithms are shown. Lumirem®, the standard oral MRCA, was found to yield incorrect attenuation values (lung) with the standard segmentation-based algorithm. The AT&PR algorithm properly recognized the stomach as a water-based filled organ. VOIs inside the stomach provided an estimate of the percentage of voxels that each AC method erroneously assigned to lung, being 60 % and 8 % with the segmentation-based and AT&PR methods, respectively (Table 6) . These values were based on the predefined attenuation values assigned to lung and soft tissue by the segmentation-based algorithm only, since the AT&PR uses a continuous scale for prediction. The diagnostic quality of the MR images with pineapple juice was similar, and the stomach was properly recognized as filled with a waterbased agent.
Discussion
Quantification in PET requires the recognition and retrospective correction of photon attenuation in tissues. Accurate AC in whole-body PET/MR systems is a challenge, since the MR signal does not directly reflect the radiodensity of tissues. While promising MR-based AC methods are being developed, the presence of abnormalities such as prostheses, metallic clips, implants and/or contrast materials remains a challenge. Clinically indicated PET/MR imaging protocols frequently entail the use of MRCA. This study was motivated by the experience from the development of CT-based AC, with the objective of investigating whether the presence of MRCA biases AC PET images reconstructed from PET/MR acquisitions. Quantitative studies evaluating the effects of CT contrast agents have demonstrated only a modest effect on PET quantification when IV and positive oral contrast agents are distributed homogeneously in the blood or bowel, respectively [34, 35] . However, accumulation of contrast agents (for example, accumulation of oral contrast agent in the stomach in patients with compromised gastrointestinal motility) has been shown to lead to a severe increase in attenuation values in CT leading to inaccuracies in PET quantification in the areas of accumulation [17] . Similarly, in PET/MR, PET quantification may be affected by the presence of MRCA either due to an increased attenuation of 511 keV photons compared to water (without being recognized as a stronger attenuator by the method used for AC) or due to MR intensity signal changes that may affect the accuracy of the algorithms used for computation of attenuation maps.
The phantom experiments performed in this study were specifically designed to investigate the first issue both with IV and with oral MRCA, while pilot human data were used to investigate the second issue. All experiments were performed only with MRCA concentrations considered to be clinically relevant. The concentrations of MRCA used can be considered an upper limit and, therefore, in most clinical cases the resulting effects could be expected to be lower, and PET quantification correspondingly less affected. In our PET/MR experiments with the NEMA phantom (phantom B), AC had to be performed using calculated CT-based attenuation maps because both the segmentation-based and the AT&PR algorithm used for creation of MR-based attenuation maps were designed for patients and do not work well with phantoms [7] . For example, phantom walls are considered as air with the segmentation-based algorithm.
We found no effect of IV MRCA in clinical concentrations on the attenuation of the PET emission signals. This is similar to the findings presented by Lee et al. [36] who investigated the influence of a different Gd-based IV MRCA using phantoms and clinical data obtained from a PET/CT system and a 3-T MR system. They demonstrated the effect of IV MRCA on PET images to be negligible, both quantitatively and qualitatively. We concur with their results. However, in indications such as MR angiography (MRA) combined with PET, the MRCA dose may be higher than in standard contrast-enhanced MR examinations, and the injected contrast agent bolus can reach concentrations of about 2 % [37] . Nonetheless, such a bolus would last for about 10 s [38, 39] , which is very short compared to PET acquisitions of several minutes, and therefore would not be expected to influence the acquisition. However, in the special case of simultaneous MRA and dynamic PET acquisitions with very short early frame durations, a potential influence of IV MRCA leading to an underestimation of PET quantitative values cannot be excluded without further dedicated studies. In clinical routine, IV MRCA is administered after the acquisition of a native, non-enhanced MR scan and attenuation maps can therefore be derived from the non-enhanced MR images, avoiding any interference of the IV MRCA. In addition, our patient data demonstrated that the attenuation maps were not affected by the presence of IV MRCA.
In clinical routine, oral MRCA are administered much less frequently than IV MRCA. However, oral MRCA are ingested prior to the scan, thus eliminating the option of performing a non-enhanced MR scan first with the patient in the same position on the examination table. Our phantom study using realistic distributions of contrast and activity inside the body showed that there is no effect of oral MRCA on the attenuation of PET emission signals. Our human studies showed that attenuation maps may be biased after ingestion of standard iron oxide-based oral MRCA when the standard segmentation-based method is used. In this case, attenuation values of lung instead of soft tissue are assigned to the majority of the stomach voxels. However, our phantom experiments demonstrated that differences in the PET values of lesions located near the area of contrast accumulation are below 3 %. Thus, focal areas may cause a bias that is lower than the known bias in segmentation-based AC PET/MR when bone is assigned the attenuation values of soft tissue [40] . The effect is only important in the volume of accumulation of oral MRCA. We found that the use of advanced algorithms for the calculation of attenuation maps, such as the AT&PR algorithm, can yield unbiased attenuation maps (Fig. 3) . In clinical routine, oral MRCA is mostly administered for cholangiography. However, the administration of oral contrast agent is not mandatory [41] and alternative oral MRCA, such as pineapple juice [32, 33] , can be also used without biasing attenuation maps. Therefore, whether iron oxide-based oral contrast agent is really needed for PET/MR examinations if segmentation-based AC is applied should be a matter of discussion.
Limitations
In the case of simultaneous MRA and dynamic PET acquisitions with very short early frame durations, a potential influence of IV MRCA leading to an underestimation of PET quantitative values cannot be excluded without further dedicated studies. AC PET values measured before and after administration of IV MRCA could not be directly compared due to the different study conditions, such as differences in the uptake a b c Fig. 3 MR images in a volunteer imaged with the PET/ MR before and after ingestion of oral MRCA. The top row shows the non-enhanced study, the middle row the study performed after the ingestion of 300 ml Lumirem®, and the bottom row the study after ingestion of 400 ml pineapple juice. For each study, coronal views of the in-phase 3-D FLASH MR sequence (a) and the corresponding MR-based attenuation maps calculated with the segmentation-based algorithm (b) and AT&PR algorithm (c) are shown. Lumirem® yields incorrect attenuation values (lung instead of water-based tissue) in the stomach (arrows) when the standard segmentation-based algorithm is used. With pineapple juice the stomach is correctly recognized as waterbased tissue with both AC methods time, the number of bed positions, and the slightly variable location of the VOI because of patient movement between the non-enhanced and contrast-enhanced examinations. This pilot study with only one patient injected with IV MRCA and one volunteer given oral MRCA provides an early indication that the use of IV MRCA in PET/MR imaging does not bias PET quantification while oral ironcontaining contrast agents should be used with caution. However, further studies including a larger patient sample are needed to rule out occasional influences of MRCA on segmentation-based AC methods.
Conclusion
We studied the effect of IV and oral MRCA on PET quantification in combined PET/MR imaging. Our results indicate that IV and oral MRCA do not produce substantial additional attenuation of PET emission signals in clinically relevant PET/ MR imaging scenarios. PET attenuation maps are not biased after administration of IV MRCA. However, PET attenuation maps may be biased after ingestion of standard iron oxidebased oral MRCA when standard segmentation-based AC algorithms are used. Advanced AC algorithms, such as AT&PR, can yield unbiased attenuation maps. Alternative oral contrast materials, such as pineapple juice, can also be used without biasing MR-based attenuation coefficients.
